TAK-186

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameTAK-186
Drug Alias NameEGFR x CD3 COBRAMVC-101TAK-186
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsEpidermal growth factor receptor erbB1 modulators
TargetsT cell surface glycoprotein CD3Epidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPresage Biosciences IncTakeda Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A